
    
      This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a
      4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998,
      followed by a 1-week safety follow-up period after the last dose of study medication.

      Subjects will participate for a total of up to 9 weeks, including screening, the 4-week
      treatment period and follow-up.
    
  